<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: August 5, 1997
(Date of earliest event reported)
LIDAK PHARMACEUTICALS
(Exact name of registrant as specified in its charter)
CALIFORNIA
(State or other jurisdiction of incorporation)
0-18734 33-0314804
(Commission File Number) (IRS Employer Identification No.)
11077 North Torrey Pines Road, La Jolla, California 92037
(Address of principal executive offices) (Zip code)
(619) 558-0364
(Registrants telephone number, including area code)
<PAGE> 2
Item 5. OTHER EVENTS
The registrant incorporates by reference herein the press release dated
August 5, 1997, attached hereto as Exhibit 99.
Item 7. Financial Statements and Exhibits
(c) Exhibits
(i) Exhibit 99 -- Press Release dated August 5, 1997.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LIDAK PHARMACEUTICALS
Date: August 7, 1997 By: \s\ David H. Katz
------------------------------
David H. Katz, M.D.
President & Chief Executive Officer
<PAGE> 1
EXHIBIT 99
LIDAK PHARMACEUTICALS
NEWS RELEASE
DATE: AUGUST 5, 1997 CONTACT: Lisa Dawn Katz
Director, Corporate
RELEASE DATE: IMMEDIATE Communications &
Investor Relations
LIDAK Pharmaceuticals
(619) 558-0364, ext. 256
David H. Katz, M.D.
President/CEO
LIDAK Pharmaceuticals
(619) 450-1538
LIDAK PHARMACEUTICALS APPOINTS SUSAN YEAGLEY SULLIVAN
AS NEW CHIEF FINANCIAL OFFICER
LA JOLLA, CALIFORNIA -- August 5, 1997 -- LIDAK Pharmaceuticals (NASDAQ
NNM: LDAKA) has appointed Susan Yeagley Sullivan, a CPA with over 20 years of
financial management experience, as vice president and chief financial officer.
Ms. Yeagley Sullivan comes to LIDAK upon departing her position, held since
1991, as senior vice president finance and treasurer at PMR Corporation, a
publicly-traded behavioral health care company with $50 million in annual
revenues and 900 employees in 45 locations. Prior to PMR Corporation, she was
vice president of finance from 1987-1991 for the Parkview Development Company, a
real estate developer involved in acquisition, development, construction and
property management of commercial property. Ms. Yeagley Sullivan has also served
as chief financial officer for Allied Home Health, controller for The Talmadge
Tinsley Co., construction controller for the U.S. headquarters of Cadillac
Fairview Urban Development, and controller for Southwood Mental Health Center.
In addition, her experience is augmented by six years at Ernst & Young and
Kenneth Leventhal & Company. Ms. Yeagley Sullivan holds a BS in accounting and
an MBA in Finance. She holds professional membership in the Financial Executives
Institute, the American Institute of Certified Public Accountants, the
California Society of Certified Public Accountants and the American Women's
Society of Certified Public Accountants.
Commenting on the appointment, David H. Katz, M.D., LIDAK's president and
chief executive officer, stated, "We are delighted to be adding such an
outstanding financial professional to our senior management team. Susan's broad
based knowledge of SEC regulations and procedures, as well as her significant
experience and expertise in financial reporting, acquisitions, cash management,
contract negotiations, and bank relations and financing will be extremely
valuable to LIDAK."
LIDAK Pharmaceuticals is developing therapeutic products against virally
caused diseases, inflammatory disorders and cancer. LIDAK recently completed the
patient enrollment and treatment portion of two Phase 3 clinical trials studying
its proprietary drug, n-docosanol (LIDAKOL(R)) as a treatment for oral herpes.
The studies were conducted on more than 600 patients at 22 clinical sites around
the United States. The Company anticipates data availability during the summer
of 1997, as previously reported.
# # #
The information contained in this press release, including any forward
looking statements contained herein, should be reviewed in conjunction with the
Company's Annual Report on Form 10-K and other publicly available information
regarding the Company, copies of which are available from the Company upon
request. Such publicly available information sets forth many risks and
uncertainties related to the Company's business and such statements, including
risks and uncertainties related to drug development and clinical trials.
